Biomarker‐based stability in limbic‐predominant amnestic mild cognitive impairment

Abstract

In a large series of clinically comparable subjects with aMCI at baseline, the specific [¹⁸ F]FDG-PET limbic-predominant hypometabolism pattern was associated with clinical stability, making progression to AD very unlikely. The identification of a biomarker-based benign course in aMCI subjects has important implications for prognosis and in planning clinical trials.